Entera Bio
ENTX
14 hedge funds and large institutions have $30.6M invested in Entera Bio in 2021 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 1 increasing their positions, 4 reducing their positions, and 3 closing their positions.
304% more capital invested
Capital invested by funds: $7.57M → $30.6M (+$23M)
200% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 3
75% more funds holding
Funds holding: 8 → 14 (+6)
33% more call options, than puts
Call options by funds: $1.69M | Put options by funds: $1.27M
13.16% more ownership
Funds ownership: 8.37% → 21.53% (+13%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
75% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$8.7M |
| 2 |
KCM
Knoll Capital Management
Miami,
Florida
|
+$2.56M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$248K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$247K |
| 5 |
Verition Fund Management
Greenwich,
Connecticut
|
+$113K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$459K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
-$48K |
| 3 |
Millennium Management
New York
|
-$14.2K |
| 4 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$4.16K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$2.19K |
ENTX Hedge Fund Activity: Q2 2021 in Review
14 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Entera Bio (ENTX) for Q2 2021, worth a combined $30.6M — up 304% from $7.57M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new ENTX positions and 3 closed out — a net gain of 6 holders — while 1 added to existing stakes and 4 trimmed.
The largest buyer was RA Capital Management, opening a new position worth an estimated $8.7M. The largest seller was Renaissance Technologies, exiting entirely with an estimated $459K sold.
- 14 institutional investors held Entera Bio (ENTX) as of Q2 2021, up from 8 in Q1 2021.
- Funds reported $30.6M of Entera Bio stock for Q2 2021, up 304% quarter-over-quarter.
- 9 funds opened new Entera Bio positions in Q2 2021 and 3 closed out, a net change of +6 holders.
- The largest Entera Bio buyer in Q2 2021 was RA Capital Management, an estimated $8.7M added.
- The largest Entera Bio seller in Q2 2021 was Renaissance Technologies, an estimated $459K sold.
Based on aggregated 13F filings for Q2 2021.